Icatibant Injection is FDA-approved, so patients can be assured it is made with quality ingredients and is safe and effective. Fresenius Kabi’s generic option uses the same active ingredient as Firazyr®*, has the same intended use, and is also administered subcutaneously.
Fresenius Kabi, in partnership with the US Hereditary Angioedema Association, hosted a webinar for healthcare providers, patients, and caregivers who are considering switching to a generic drug therapy to treat acute attacks of hereditary angioedema (HAE).
| Reference List Drug | Approved AP Generic | Therapeutically Equivalent | |
|---|---|---|---|
| Name | Firazyr® | lcatibant Injection | |
| Condition of Use (Indications) | It is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older | It is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older | |
| Drug Form | Sterile solution | Sterile solution | |
| Route of Administration | Subcutaneous injection in the abdominal area | Subcutaneous injection in the abdominal area | |
| Active Ingredient | Icatibant Acetate | Icatibant Acetate | |
| Strength | 30 mg per 3 mL | 30 mg per 3 mL | |
| Excipients | Sodium Chloride, Water for lnjection USP, Glacial Acetic Acid, Sodium Hydroxide, NF | ||
*FIRAZYR® is a registered trademark of Shire, a Takeda company.
References
*FIRAZYR® is a registered trademark of Shire, a Takeda company.
